Pharmaceutical company Boehringer Ingelheim has wholly acquired Amal Therapeutics from VCs including High-Tech Gründerfonds (HTGF), VI Partners and BioMedPartners.
Fund, which has already been invested in at least one transaction, has a €1bn target
Pechel, via Pechel IV, and the co-investment team of Omnes back the French IT services firm
Connection Capital provided £6.7m to support the buyout of the business in 2017
Temasek previously led a £7m investment for the technology developer in 2016